Literature DB >> 23641277

Strategy of Infection Control in Immunosuppressive Therapy for ANCA-Associated Vasculitis.

Masaharu Yoshida1.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) are well known to be associated with small vessel vasculitic diseases such as microscopic polyangiitis (MPA), allergic granulomatous angiitis (AGA), and Granulomatosis with poly angiitis: GPA (Wegener's). Disease assessment by 1) vasculitic activity, 2) damage resulting from vasculitis, and 3) patient function, were the required endpoints for the therapeutic trials in ANCA-associated vasculitis (AAV). Harmonized steroids and cyclophosphamide or azathioprine are effective for active AAV. In evaluating tools for monitoring disease, titers of ANCA and the levels of CRP were found useful in AAV. However, it will be important for clinicians to observe AAV patients more closely and reduce immunosuppressive drug doses more cautiously, especially to prevent several infections (i.e., deep mycosis, pneumocystis jirovecii pneumonia and cytomegalovirus). We indicated that strategy of infection control in immunosuppressive therapy for AAV. (J Jpn Coll Angiol, 2009, 49: 93-99).

Entities:  

Keywords:  ANCA associated vasculitis; compromized host; immunosuppressive therapy; infection control

Year:  2013        PMID: 23641277      PMCID: PMC3634993          DOI: 10.3400/avd.ra.12.00092

Source DB:  PubMed          Journal:  Ann Vasc Dis        ISSN: 1881-641X


  6 in total

1.  Anti-fungal activity of sulfamethoxazole toward Aspergillus species.

Authors:  Shunsuke Hida; Masaharu Yoshida; Iwao Nakabayashi; Noriko N Miura; Yoshiyuki Adachi; Naohito Ohno
Journal:  Biol Pharm Bull       Date:  2005-05       Impact factor: 2.233

2.  Role of anti-beta-glucan antibody in host defense against fungi.

Authors:  Ken-Ichi Ishibashi; Masaharu Yoshida; Iwao Nakabayashi; Hiroyasu Shinohara; Noriko N Miura; Yoshiyuki Adachi; Naohito Ohno
Journal:  FEMS Immunol Med Microbiol       Date:  2005-04-01

3.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

Authors:  E Reinhold-Keller; N Beuge; U Latza; K de Groot; H Rudert; B Nölle; M Heller; W L Gross
Journal:  Arthritis Rheum       Date:  2000-05

4.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

5.  Rapid decrease of anti-beta-glucan antibody as an indicator for early diagnosis of carinii pneumonitis and deep mycotic infections following immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Masaharu Yoshida; Ken-ichi Ishibashi; Shunsuke Hida; Noriko Yoshikawa; Iwao Nakabayashi; Masakazu Akashi; Taeko Watanabe; Tomohiro Tomiyasu; Naohito Ohno
Journal:  Clin Rheumatol       Date:  2009-02-04       Impact factor: 2.980

6.  Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study.

Authors:  Shoichi Ozaki; Tatsuya Atsumi; Taichi Hayashi; Akihiro Ishizu; Shigeto Kobayashi; Shunichi Kumagai; Yasuyuki Kurihara; Manae S Kurokawa; Hirofumi Makino; Hiroko Nagafuchi; Kimimasa Nakabayashi; Norihiro Nishimoto; Machi Suka; Yasuhiko Tomino; Hidehiro Yamada; Kunihiro Yamagata; Masaharu Yoshida; Wako Yumura; K Amano; Y Arimura; K Hatta; S Ito; H Kikuchi; E Muso; H Nakashima; Y Ohsone; Y Suzuki; H Hashimoto; A Koyama; S Matsuo; H Kato
Journal:  Mod Rheumatol       Date:  2011-09-18       Impact factor: 3.023

  6 in total
  1 in total

1.  Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.

Authors:  Liu Yang; Honglang Xie; Zhengzhao Liu; Yinghua Chen; Jinquan Wang; Haitao Zhang; Yongchun Ge; Weixin Hu
Journal:  BMC Nephrol       Date:  2018-06-14       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.